Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Argenx Se ADR (NQ: ARGX )

596.00 +4.56 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Argenx Se ADR

< Previous 1 2 3 Next >
argenx to Participate at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
From argenx SE
Via GlobeNewswire
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
From argenx SE
Via GlobeNewswire
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
From argenx SE
Via GlobeNewswire
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
From argenx SE
Via GlobeNewswire
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
From argenx SE
Via GlobeNewswire
argenx to Present at BofA Securities 2024 Health Care Conference
From argenx SE
Via GlobeNewswire
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
From argenx SE
Via GlobeNewswire
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
From argenx SE
Via GlobeNewswire
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
From argenx SE
Via GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
From argenx SE
Via GlobeNewswire
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
From argenx SE
Via GlobeNewswire
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
From argenx SE
Via GlobeNewswire
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
5 medical stocks growing earnings by triple digits
There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
Via MarketBeat
Topics Economy
Exposures Economy
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
argenx Highlights 2024 Strategic Priorities
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.